Wright Richard M. 4
4 · Celldex Therapeutics, Inc. · Filed Jun 5, 2024
Insider Transaction Report
Form 4
Wright Richard M.
Other
Transactions
- Sale
Common Stock
2024-06-03$33.53/sh−27,580$924,658→ 40,097 total - Exercise/Conversion
Common Stock
2024-06-03$2.78/sh+20,625$57,337→ 20,833 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2024-06-03−18,375→ 23,625 totalExercise: $22.48Exp: 2032-06-16→ Common Stock (18,375 underlying) - Sale
Common Stock
2024-06-03$33.99/sh−19,264$654,695→ 20,833 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2024-06-03−20,625→ 0 totalExercise: $2.78Exp: 2029-06-19→ Common Stock (20,625 underlying) - Exercise/Conversion
Incentive Stock Option (right to buy)
2024-06-03−28,469→ 13,531 totalExercise: $28.00Exp: 2031-06-17→ Common Stock (28,469 underlying) - Exercise/Conversion
Common Stock
2024-06-03$28.00/sh+28,469$797,132→ 49,302 total - Exercise/Conversion
Common Stock
2024-06-03$22.48/sh+18,375$413,070→ 67,677 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.81 to $33.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.815 to $34.20 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
- [F3]As of June 19, 2023, the option is fully vested.
- [F4]25% vested on June 17, 2022 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
- [F5]25% vested on June 16, 2023 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.